CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-08-02 | Gibson Christopher Chief Executive Officer | Exercise or conversion | +31,250 | $2.48 | $78K | 955,734 |
| 2023-08-02 | Gibson Christopher Chief Executive Officer | Sale | −60,955 | $13.02 | $793K | 894,779 |
| 2023-08-02 | Gibson Christopher Chief Executive Officer | Sale | −4,060 | $13.36 | $54K | 890,719 |
| 2023-08-02 | Gibson Christopher Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −8,674 | 407,676 | ||
| 2023-08-02 | Gibson Christopher Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −31,250 | 531,250 | ||
| 2023-07-29 | Larson Tina Marriott President and COO | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −8,000 | 532,000 | ||
| 2023-07-27 | Larson Tina Marriott President and COO | Exercise or conversion 10b5-1 | +8,000 | $1.06 | $8K | 432,160 |
| 2023-07-27 | Larson Tina Marriott President and COO | Sale 10b5-1 | −3,627 | $13.12 | $48K | 428,533 |
| 2023-07-27 | Larson Tina Marriott President and COO | Sale 10b5-1 | −4,373 | $14.05 | $61K | 424,160 |
| 2023-07-26 | Virani Shafique Chief Business Officer | Exercise or conversion 10b5-1 | +20,000 | $2.22 | $44K | 163,954 |
| 2023-07-26 | Virani Shafique Chief Business Officer | Sale 10b5-1 | −20,000 | $14.41 | $288K | 143,954 |
| 2023-07-26 | Virani Shafique Chief Business Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −20,000 | 469,469 | ||
| 2023-07-25 | Virani Shafique Chief Business Officer | Exercise or conversion 10b5-1 | +20,000 | $2.22 | $44K | 163,954 |
| 2023-07-25 | Virani Shafique Chief Business Officer | Sale 10b5-1 | −20,000 | $14.30 | $286K | 143,954 |
| 2023-07-25 | Virani Shafique Chief Business Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −20,000 | 489,469 | ||
| 2023-07-25 | Borgeson Blake Director | Sale | −18,719 | $14.61 | $273K | 7,487,385 |
| 2023-07-20 | Gibson Christopher Chief Executive Officer | Conversion | +10,000 | 925,810 | ||
| 2023-07-20 | Gibson Christopher Chief Executive Officer | Gift | −10,000 | 915,810 | ||
| 2023-07-20 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock | −10,000 | 6,531,496 | ||
| 2023-07-19 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +37,500 | $2.22 | $83K | 867,913 |
Page 34 of 41 · 805 trades